Pulmocide raised $30.4 million in a Series B round of financing to support the early clinical development of its lead inhaled drugs against respiratory syncytial virus (RSV) and pulmonary aspergillosis. The fundraising round was led by new investor SR One and included the Longwood Fund and existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation–JJDC, and Touchstone Innovations.
{iframe}http://www.genengnews.com/gen-news-highlights/pulmocide-raises-304m-for-clinical-development-of-inhaled-respiratory-drugs/81254052{/iframe}